Pharmacology of immunosuppressive medications used in renal diseases and transplantation

American Journal of Kidney Diseases

Volumn 28, Issue 5, 1996, Pages 631-667

  De Mattos, Angelo M ^a   Olyaei, Ali J ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

immunosuppressive drugs; Pharmacology; renal disease; renal transplantation

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CALCINEURIN; CHLORAMBUCIL; COLCHICINE; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DEFLAZACORT; DILTIAZEM; ENZYME INHIBITOR; FISH OIL; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSINATE DEHYDROGENASE; INTERLEUKIN 2; KETOCONAZOLE; LYMPHOCYTE ANTIBODY; MACROLIDE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; SARCOLYSIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; ENDOCRINE DISEASE; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LUNG TOXICITY; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; SERUM SICKNESS;

EID: 0029964976     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(96)90246-2     Document Type: Review

References (333)

1. Elion GB: The pharmacology of azathioprine. Ann N Y Acad Sci 685:401-407, 1993
2. Cory JG: Purine and pyrimidine nucleotide metabolism, in Devlin TM (ed): Textbook of Biochemistry: With Clinical Correlations (ed 3). New York, NY, Wiley-Liss, 1992, pp 529-573
3. St Georgiev V: Enzymes of the purine metabolism: Inhibition and therapeutic potential. Ann N Y Acad Sci 685:207-216, 1993
4. Chan GLC, Canafax DM, Johnson CA: The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 7:165-177, 1987
5. Chocair PR, Duley JA, Simmonds HA, Cameron JS:The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 53:1051-1056, 1992
6. Allison AC, Eugui EM: Inhibitors of de novo purine and pyrimidine synthesis as immunosuppressive drugs. Transplant Proc 25:8-18, 1993
7. Lu CY, Sicher SC, Vazquez MA: Prevention and treatment of renal allograft rejection: New therapeutic approaches and new insights into established therapies. J Am Soc Nephrol 4:1239-1256, 1993
8. Mitchell BS, Dayton JS, Turka LA, Thompson CB: IMP dehydrogenase inhibitors as immunomodulators. Ann N Y Acad Sci 685:217-224, 1993
9. Lennard I, Brown CB, Fos M, Maddocks JL: Azathioprine metabolism in kidney transplant recipients. Br J Clin Pharmacol 18:693-700, 1984
10. Pollak R, Nishikawa RA, Mozes M, Johasson O: Azathioprine-induced leukopenia: Clinical significance in renal transplantation. J Surg Res 29:258-264, 1980
11. DeClerck YA, Ettinger RB, Ortega JA, Pennisi AJ: Macrocytosis and pure RBC anemia caused by azathioprine. Am J Dis Child 134:377-379, 1980
12. Sparburg M, Simon N, DeGreco F: Intrahepatic cholestasis due to azathioprine. Gastroenterology 57:439-441, 1969
13. Pettrelli M, Ricanati ES, McCullough AJ: Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 104:651-655, 1986
14. Ware AJ, Luby JP, Hollinger B, Elgenbrodt EH, Cuthbert JA, Atkins CR, Shorey J, Huyll AR, Conbes B: Etiology of liver diseases in renal transplantation patients. Ann Intern Med 91:364-371, 1979
15. Weir M, Kirkman RL, Strom TB, Tilney NL: Liver disease in recipients of long functioning renal allografts. Kidney Int 28:839-844, 1985
16. Bedrossian CW, Sussman J, Conklin RH, Kahan BD: Azathioprine associated interstitial pneumonitis. Am J Clin Pathol 82:148-154, 1984
17. Donadio JV, Jr, Glassock RJ: Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 21:239-250, 1993
18. Ponticelli C, Passerini P: Alkylating agents and purine analogues in primary glomerulonephritis with nephrotic syndrome. Nephrol Dial Transplant 6:381-388, 1991
19. Cade R, Mars D, Privette M, Thompson R, Croker B, Peterson J, Campbell K: Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Arch Intern Med 146:737-741, 1986
20. Keller F, Oehlenberg B, Kunzendorf U, Schwarz A, Offermann G: Long-term treatment and prognosis of rapidly progressive glomerulonephritis. Clin Nephrol 31:190-197, 1989
21. Bullingham RES, Nicholls A, Hale M: Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 28:925-929, 1996
22. Yatscoff RW, Keenan R, LeGatt DF: Single-dose pharmacokinetics of the new immunosuppressant RS-61443 in the rabbit. Ther Drug Monit 15:400-404, 1993
23. Roche: CellCept (mycophenolate mofetil capsules) (package insert). Roche, Nutley, NJ, June 1995
24. Eugui EM, Allison AC: Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 685:309-329, 1993
25. Allison AC, Eugui EM: Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 26:3205-3210, 1994
26. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM: Mycophenolic acid and Brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 25:67-70, 1993 (suppl 2)
27. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS: Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87:940-948, 1991
28. Cohen MB, Maybaum J, Sadee W: Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells. J Biol Chem 256:8713-8717, 1981
29. Dayton JS, Turka LA, Thompson CB, Mitchell BS: Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 41:671-676, 1992
30. Morris RE: New small molecule immunosuppressants for transplantation: Review of essential concepts. J Heart Lung Transplant 12:8275-5286, 1993
31. Hullett DA, Sollinger HW: Mycophenolate mofetil and brequinar sodium: New immunosuppressive agents. Transplant Proc 25:45-47, 1993 (suppl 2)
32. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995
33. Deierhoi MH, Kauffman RS, Hudson SL, Barber WH, Phil D, Curtis JJ, Julian BA, Gaston RS, Laskow DA, Diethelm AG: Experience with mycophenolate mefetil (RS61443) in renal transplantation at a single center. Ann Surg 217:476-484, 1993
34. Sollinger HW, Beizer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT, Tomlanovich SJ: RS-61443 (mycophenolate mofetil): A multicenter study for refractory kidney transplant rejection. Ann Surg 216:513-518, 1992
35. Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232, 1995
36. Tricontinental mycophenolate mofetil renal transplantation study group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029-1037, 1996
37. Calabresi P, Chabner BA: Antineoplastic agents, in Gilman AG, Rall TW, Niew AS, et al (eds): Goodman and Gilman's The Pharmalogical Basis of Therapeutics. New York, NY, Pergamon, 1990, pp 1209-1236
38. Fraiser LH, Kanekal S, Kehrer JP: Cyclophosphamide toxicity. Drugs 42:781-795, 1991
39. Rondeau E, Kourilsky O, Peraldi M-N, Alberti C, Kanfer A, Sraer J-D: Methylprednisolone and cyclophosphamide pulse therapy in crescentic glomerulonephritis: Safety and effectiveness. Ren Fail 15:495-501, 1993
40. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS: Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 89:403-410, 1990
41. Kunis CL, Kiss B, Williams G, D'Agati V, Appel GB: Intravenous "pulse" cyclophosphamide therapy of crescentic glomerulonephritis. Clin Nephrol 37:1-7, 1992
42. Austin HA III, Klippel JH, Balow JE, Le Riche NGH, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. N Engl J Med 314:614-619, 1986
43. Vogelzang NJ: Nephrotoxicity from chemotherapy: Prevention and management. Oncology 5:97-110, 1991
44. Patterson WP, Khojasteh A: Ifosfamide induced renal tubular defects. Cancer 63:649-651, 1989
45. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318:1423-1431, 1988
46. Levey AS, Lan S-P, Corwin HL, Kasinath BS, Lachin J, Neilson EG, Hunsicker LG, Lewis EJ, The Lupus Nephritis Collaborative Study Group: Progression and remission of renal disease in the lupus nephritis collaborative study. Ann Intern Med 116:114-123, 1992
47. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76-85, 1983
48. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM: Cyclophosphamide pulse therapy in Wegener' s granulomatosis. Nephrol Dial Transplant 6:531-535, 1991
49. Palmer A, Cairns T, Dische F, Gluck G, Gjorstrup P, Parsons V, Welsh K, Taube D: Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 6:536-542, 1991
50. Couser WG: Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11:449-464, 1988
51. Ponticelli C, Passerini P: The natural history and therapy of idiopathic membranous nephropathy. Nephrol Dial Transplant 1:37-41, 1990 (suppl)
52. Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS : Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 37:229-234, 1992
53. Bruns FJ, Adler S, Fraley DS, Segel DP: Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 114:725-730, 1991
54. Falk RJ, Hogan SL, Muller KE, Jennette JC, Glomerular Disease Collaborative Network: Treatment of progressive membranous glomerulopathy: A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. Ann Intern Med 116:438-445, 1992
55. Maezawa A, Hiromura K, Mitsuhashi H, Tsukada Y, Kanai H, Yano S, Naruse T: Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. Clin Nephrol 42:30-32, 1994
56. Gertz MA, Kyle RA, Greipp PR: Response rates and survival in primary systemic amyloidosis. Blood 77:257-262, 1991
57. Goddard IR, Jackson R, Boulton Jones JM: AL amyloidosis: Therapeutic response in two patients with renal involvement. Nephrol Dial Transplant 6:592-594, 1991
58. Niaudet P, French Society of Paediatric Nephrology: Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: A multicentre randomized controlled trial. Pediatr Nephrol 6:1-3, 1992
59. Haynes RC, Murad F: Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of adrenocortical steroid biosynthesis, in Gilman AG, Goodman LS (eds): The Pharmacological Basis of Therapeutics (ed 7). New York, NY, Macmillan, 1993, pp 1459-1489
60. Hume DM, Merrill JP, Miller BF, Thorn GW: Experiences with renal homotransplantation in the human: Report of nine cases. J Clin Invest 34:327-382, 1955
61. Starzl TE, Marchioro TL, Waddell WR: The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 117:385-395, 1963
62. Jusko WJ, Ludwig EA: Corticosteroids, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics - Principles of Therapeutic Drug Monitoring (ed 3). Vancouver, WA, Applied Therapeutics, 1992, pp 27-1-27-34
63. English J, Dunne M, Marks V: Diurnal variation in prednisolone kinetics. Clin Pharmacol Ther 33:381-385, 1983
64. Rose JQ, Nickelsen JA, Ellis EF, Middleton E, Jusko WJ: Prednisolone disposition in steroid-dependent asthmatic children. J Allergy Clin Immunol 67:188-193, 1981
65. Miller PFW, Bowmer CJ, Wheeldon J, Brocklebank JT: Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child 65:196-200, 1990
66. Jusko WJ, Milad MA, Ludwig EA, Lew KH, Kohli RK: Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. Clin Nephrol 43:S16-S19, 1995
67. Gambertoglio JG, Amend WJC, Benet LZ: Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review. J Pharmacokinet Biopharm 8:1-47, 1980
68. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE: Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates. Ann Intern Med 119:1198-1208, 1993
69. Karin M, Yang-Yen H-F, Chambard J-C, Deng T, Saatcioglu F: Various modes of gene regulation by nuclear receptors for steroid and thyroid hormones. Eur J Clin Pharmacol 45:S9-S15, 1993
70. Miesfeld RL: Molecular genetics of corticosteroid action. Am Rev Respir Dis 141:811-817, 1990
71. Munck A, Mendel DB, Smith LI, Orti E: Glucocorticoid receptors and actions. Am Rev Respir Dis 141:S2-S10, 1990
72. Wright APH, Zilliacus J, McEwan IJ, Dahlman-Wright K, Almlof T, Carlstedt-Duke J, Gustafsson J: Structure and function of the glucocorticoid receptor. J Steroid Biochem Mol Biol 47:11-19, 1993
73. Ray A, Sehgal PB: Cytokines and their receptors: Molecular mechanism of interleukin-6 gene repression by glucocorticoids. J Am Soc Nephrol 2:S214-S221, 1992
74. Yang-Yen H-F, Chambard J-C, Sun Y-L, Smeal T, Schmidt TJ, Drouin J, Karin M: Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62:1205-1215, 1990
75. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, Verma IM, Evans RM: Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62:1217-1226, 1990
76. Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, Meco D, Petrangeli E, Frati L, Gulino A: Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175:637-646, 1992
77. Krane SM: Some molecular mechanisms of glucocorticoid action. Br J Rheumatol 32:3-5, 1993
78. Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT: Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 91:1481-1489, 1993
79. Schleimer RP: An overview of glucocorticoid antiinflammatory actions. Eur J Clin Pharmacol 45:S3-S7, 1993
80. AyanlarBatuman O, Ferrero AP, Diaz A, Jimenez SA: Regulation of transforming growth factor-β1 gene expression by glucocorticoids in normal human T lymphocytes. J Clin Invest 88:1574-1580, 1991
81. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-kB activity through induction of IkB synthesis. Science 270:286-290, 1995
82. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS, Jr: Role of transcriptional activation of IkBα in mediation of immunosuppression of glucocorticoids. Science 270:283-286, 1995
83. Williams TJ, Yarwood H: Effect of glucocorticosteroids on microvascular permeability. Am Rev Respir Dis 141:S39-S43, 1990
84. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC: Dexamethasone inhibition of interleukin 1 beta production by human monocytes. J Clin Invest 81:237-244, 1988
85. Han J, Thompson P, Buetler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172:391-394, 1990
86. Pfeilschifter J, Muhl H, Pignat W, Märki F, van den Bosch H: Cytokine regulation of group II phospholipase A2 expression in glomerular mesangial cells. Eur J Clin Pharmacol 44:S7-S9, 1993
87. Rota S, Rambaldi A, Gaspari F, Noris M, Daina E, Benigni A, Perna A, Donadelli R, Remuzzi G, Garattini S: Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney Int 42:981-990, 1992
88. Coyne DW, Nickols M, Bertrand W, Morrison AR: Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids. Am J Physiol 263:F97-F102, 1992
89. O'Banion MK, Winn VD, Young DA: c-DNA cloning and functional activity of a glucocordcoid-related inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 89:4888-4892, 1992
90. Radomski MW, Palmer RMJ, Moncada S: Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A 87:10043-10047, 1990
91. Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA, Wang SC, Simmons RL, Billiar TR: Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A 90:522-526, 1993
92. Gambertoglio T, Frey F, Holford N, Birnbaum JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O, Amend WJ: Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int 21:621-626, 1982
93. Gambertoglio JG, Holford NH, Lizak PS, Birnbaum JL, Salvatierra O, Amend WJ: The absence of effect of azathioprine on prednisolone pharmacokinetics following maintenance prednisone doses in kidney transplant patients. Am J Kidney Dis 3:425-429, 1984
94. Friedman JE, Yun JS, Patel YM, McGrane MM, Hanson RW: Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J Biol Chem 268:12952-12957, 1993
95. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS: Hyperlipidemia in renal transplant recipients: Natural history and response to treatment. Medicine 73:215-223, 1994
96. Sharma AK, Myers TA, Hunninghake DB, Matas AJ, Kashtan CE: Hyperlipidemia in long-term survivors of pediatric renal transplantation. Clin Transplant 8:252-257, 1994
97. Ingulli E, Tejani A, Markell M: The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children posttransplantation in the cyclosporine era. Transplantation 55:1029-1033, 1993
98. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 112:352-364, 1990
99. Russell RGG: Cellular regulatory mechanisms that may underlie the effects of corticosteroids on bone. Br J Rheumatol 32:6-10, 1993
100. Hodgson SF: Corticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am 19:95-111, 1990
101. Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311, 1995
102. Scudeletti M, Castagnetta L, Imbimbo B, Puppo F, Pierri I, Indiveri F: New glucocorticoids. Ann N Y Acad Sci 595:368-382, 1990
103. Avioli LV: Potency ratio - A brief synopsis. Br J Rheumatol 32:24-26, 1993 (suppl 2)
104. Olgaard K, Storm T, Wowern NV, Daugaard D, Egfjord M, Lewin E, Brandi L: Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Br J Rheumatol 32:15-23, 1993 (suppl 2)
105. Ferraris JR, Pasqualini T: Therapy with a new glucocorticoid: Effects of deflazacort on linear growth and growth hormone secretion in renal transplantation. J Rheumatol 20:43-46, 1993 (suppl 37)
106. Gennari C: Differential effect of glucocorticoids on calcium absorption and bone mass. Br J Rheumatol 32:11-14, 1993 (suppl 2)
107. Elli A, Rivolta R, Di Palo FQ, Parenti M, Vergallo G, Palazzi P, Zafiropulu S, Abelli P, Zanussi C: A randomized trial of deflazacort versus 6-methylprednisolone in renal transplantation - Immunosuppressive activity and side effects. Transplantation 55:209-212, 1993
108. Davison AM: Steroid therapy in primary glomerulonephritis. Nephrol Dial Transplant 1:23-28, 1990 (suppl)
109. Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 9:368-375, 1989
110. Bruns FJ, Adler S, Fraley DS, Segel DP: Long-term follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis. Am J Med 86:400-406, 1989
111. Schena FP, Montenegro M, Scivittaro V: Meta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease). Nephrol Dial Transplant 1:47-52, 1990 (suppl)
112. D'Amico G, Sinico RA: Treatment and monitoring of systemic vasculitis. Nephrol Dial Transplant 1:53-57, 1990 (suppl)
113. Hricik DE, Almawi WY, Strom TB: Trends in the use of glucocorticoids in renal transplantation. Transplantation 57:979-989, 1994
114. Yee GC, Mcguire TR: Pharmacokinetic drug interactions with cyclosporine (part I). Clin Pharmacokinet 19:319-332, 1990
115. Yee GC, Mcguire TR: Pharmacokinetic drug interactions with cyclosporine (part II). Clin Pharmacokinet 19:400-415, 1990
116. Lake KD: Management of drug interactions with cyclosporine. Pharmacotherapy 11:1105-1188, 1991
117. Yee GC, Salomon DR: Cyclosporine, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics - Principles of Therapeutic Drug Monitoring (ed 3). Vancouver, WA, Applied Therapeutics, 1992, pp 28-1-28-40
118. Erlanger BF: Do we know the site of action of cyclosporin? Immunol Today 13):487-490, 1992
119. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136-142, 1992
120. Kunz J, Hall MN: Cyclosporin A, FK506 and rapamycin: More than just immunosuppression. Trends Biochem Sci 18:334-338, 1993
121. Andersson J, Nagy S, Groth CG, Andersson U: Effects of FK506 and cyclosporine A on cytokine production studied in vitro at a single-cell level. Immunology 75:136-142, 1992
122. Russell RGG, Graveley R, Coxon F, Skjodt H, Del Pozo E, Elford P, Mackenzie A: Cyclosporin A: Mode of action and effects on bone and joint tissues. Scand J Rheumatol 21:9-18, 1992 (suppl 95)
123. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N: The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci U S A 696:9-19, 1993
124. Schreiber SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283-287, 1991
125. Fliri H, Baumann G, Enz A, Kallen J, Luyten M, Mikol V, Movva R, Quesniaux V, Schreier M, Walkinshaw M, Wenger R, Zenke G, Zurini M: Cyclosporine: Structure-activity relationships. Ann N Y Acad Sci U S A 696:47-53, 1993
126. Friedman J, Weissman I: Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: One in the presence and one in the absence of CsA. Cell 66:799-806, 1991
127. Clipstone NA, Crabtree OR: Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs. Ann N Y Acad Sci U S A 696:20-30, 1993
128. Bierer BE, Holländer G, Fruman D, Burakoff SJ: Cyclosporin A and FK506: Molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 5:763-773, 1993
129. Fischer G, Wittman-Liebold B, Lang K, Kiefhaber T, Schmid FX: Cyclosphilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337:476-478, 1989
130. Clipstone NA, Crabtree GR: Identification of calcineurin as a key signalling enzyme in T lymphocyte activation. Nature 357:695-697, 1992
131. McCaffrey PG, Perrino BA, Soderling TR, Rao A: NF-ATp: A T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem 268:3747-3752, 1993
132. Brabletz T, Pfeuffer I, Schorr E, Siebelt F, Wirth T, Serfling E: Transforming growth factor β and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol Cell Biol 13:1155-1162, 1993
133. Henderson DJ, Naya I, Bundick RV: Comparison of the effects of FK-506, cyclosporine-A and rapamycin on IL-2 production. Immunology 73:316-321, 1991
134. Khanna A, Li B, Sehajpal PK, Sharma VK, Suthanthiran M: Mechanism of action of cyclosporine: A new hypothesis implicating transforming growth factor-β. Transplant Rev 9:41-48, 1995
135. Thomson AW: The effects of cyclosporin A on non-T cell components of the immune system. J Autoimmun 5:167-176, 1992
136. Fuleihan R, Ramesh N, Horner A, Ahern D, Belshaw PJ, Alberg DG, Stamenkovic I, Harmon W, Geha RS: Cyclosporin A inhibits CD40 ligand expression in T lymphocytes. J Clin Invest 93:1315-1320, 1994
137. Forrest MJ, Jewell ME, Koo GC, Sigal NH: FK-506 and cyclosporin A: Selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. Biochem Pharmacol 42:1221-1228, 1991
138. Hultsch T, Albers MW, Schreiber SL, Hohman RJ: Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proc Natl Acad Sci U S A 88:6229-6233, 1991
139. Xu Q, Leiva MC, Fischkoff SA, Handschumacher RE, Lyttle CR: Leukocyte chemotactic activity of cyclophilin. J Biol Chem 267:11968-11971, 1992
140. Russell RGG, Graveley R, Skjodt H: The effects of cyclosporin A on bone and cartilage. Br J Rheumatol 32:42-46, 1993
141. Sherry B, Yarlett N, Strupp A, Cerami A: Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A 89:3511-3515, 1992
142. Martin M, Neumann D, Hoff T, Resch K, Dewitt DL, Goppelt-Struebe M: Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 45:150-158, 1994
143. Tufro-McReddie A, Gomez A, Norling LL, Omar AA, Moore LC, Kaskel FJ: Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney. Kidney Int 43:615-622, 1993
144. Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, Donadelli R, Rerauzzi G: The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 54:775-780, 1992
145. Bunchman TE, Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88:310-314, 1991
146. Markell MS, Fernandez J, Naik UP, Ehrlich Y, Kornecki E: Effects of cyclosporine-A and cyclosporine-G on ADP-stimulated aggregation of human platelets. Ann N Y Acad Sci 696:404-407, 1993
147. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA: Does cyclosporin increase lipoprotein (a) concentrations in renal transplant recipients? Lancet 341:268-270, 1993
148. Webb AT, Brown EA: Letters and comments to editor: Author's reply. Lancet 341:767, 1993
149. Castelao AM, Barberá MJ, Blanco A, Fiol C, Griñó JM, Bover J, GilVernet S, Andrés E, Serón D, Castiñeiras MJ, Alsina J: Lipid metabolic abnormalities after renal transplantation under cyclosporine and prednisone immunosuppression. Transplant Proc 24:96-98, 1992
150. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW: Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 57:1479-1483, 1994
151. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS: Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 58:663-669, 1994
152. Kunzendorf U, Walz G, Brockmoeller J, Neumayer HH, Jochimsen F, Roots I, Offermann G, Strom TB: Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 52:280-284, 1991
153. Homan van der Heide JJ, Bilo HJG, Donker JM, Wilmink JM, Tegzess AM: Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 329:769-773, 1993
154. Kelley VE, Kirkman RL, Bastos M, Barrett LV, Strom TB: Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine. Transplantation 48:98-102, 1989
155. Homan van der Heide JJ, Bilo HJG, Donker AJM, Wilmink JM, Sluiter WJ, Tegzess AM: Dietary supplementation with fish oil modifies renal reserve filtration capacity in postoperative, cyclosporin A-treated renal transplant recipients. Transpl Int 3:171-175, 1990
156. Berthoux FC, Guerin C, Burgard G, Berthoux P, Alamartine E: One-year randomized controlled trial with omega3 fatty acid fish oil in clinical renal transplantation. Transplant Proc 24:2578-2582, 1992
157. McCulloch TA, Harper SJ, Donnelly PK, Moorhouse J, Bell PRF, Walls J, Feehally J, Furness PN: Influence of nifedipine on interstitial flbrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol 47:839-842, 1994
158. Kimball PM, Kerman RH, Kahan BD: Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 51:486-490, 1991
159. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699-705, 1984
160. Perico N, Remuzzi G: Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplant Rev 5:63-80, 1991
161. Kahan BD: Cyclosporine. N Engl J Med 321:1725-1738, 1989
162. Pan W-L, Chan C-P, Huang C-C, Lai M-K: Cyclosporine-induced gingival overgrowth. Transplant Proc 24:1393-1394, 1992
163. Thomason JM, Seymour RA, Rice N: The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol 20:37-40, 1993
164. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DMA, Wiesenfeld D: Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 20:286-293, 1993
165. Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M, Sigal NH: The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 176:751-760, 1992
166. Sigal NH, Dumont F, Durette P, Siekierka JJ, Peterson L, Rich DH, Dunlap BE, Staruch MJ, Melino MR, Koprak SL, Williams D, Wilzel B, Pisano JM: Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin-A? J Exp Med 172:619-628, 1991
167. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735-7738, 1987
168. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Veda K, Komano T, Hori R: Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharm Exp Ther 266:1614-1619, 1993
169. Serino F, Grevel J, Napoli KL, Kahan BD, Strobel HW: Generation of oxygen free radicals during the metabolism of cyclosporine A: A cause-effect relationship with metabolism inhibition. Mol Cell Biochem 122:101-112, 1993
170. Walker PD, Lazzaro VA, Duggin GG, Horvat JS, Tiller DJ: Evidence that alteration in renal metabolism and lipid peroxidation may contribute to nephrotoxicity. Transplantation 50:487-492, 1990
171. Bennett WM: The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43:53-57, 1995 (suppl 1)
172. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine associated chronic nephropathy. N Engl J Med 311:699-705, 1984
173. Myers BD, Newton L, Boshkos C: Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 46:694-703, 1988
174. Young EW, Ellis CN, Messana JM: A prospective study of renal structure and function in psoriasis patients treated with cyclosporine. Kidney Int 46:1216-1222, 1994
175. Zachariae H, Hansen HE, Kragballe K, Olsen S: Morphologic renal changes during cyclosporine treatment of psoriasis. J Am Acad Dermatol 26:415-419, 1992
176. Mihatsch MJ, Antonovych T, Bohman SO, Habib R, Helmchen U, Noel L-H, Olsen S, Sibley RK, Kemeny E, Feutren G: Cyclosporin A nephropathy: Standardization of the evaluation of kidney biopsies. Clin Nephrol 41:23-32, 1994
177. Bennett WM: The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43:S3-S7, 1995 (suppl 1)
178. Shulman H, Striker G, Deeg JH, Kennedy M, Storb R, Thomas ED: Nephrotoxicity of cyclosporine A after allogenic marrow transplantation: Glomerular thrombosis and tubular injury. N Engl J Med 305:1392-1395, 1981
179. Giroux L, Smeesters C, Corman J, Paquin F, Allaire G, St-Louis G, Daloze P: Hemolytic uremic syndrome in renal allografted patients treated with cyclosporin. Can J Physiol Pharmacol 65:1125-1131, 1987
180. Curtiss JJ: Hypertension and kidney transplantation. Am J Kidney Dis 7:181-196, 1986
181. Bennett WM, Burdmann EA, Andoh TF, Houghton DC, Lindsley J, Elzinga LW: Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 9:141-145, 1994
182. Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC, Jr, Gores G, Hay E, Dickson ER, Krom RA: Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 55:1332-1339, 1993
183. Barros EJG, Boim MA, Ajzen H, Ramos OL, Schor N: Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int 32:19-25, 1985
184. Bantle JP, Paller MS, Bourdreau RM, Olivari MT, Ferris TF: Long-term effects of cyclosporine on renal function in organ transplant recipients. J Lab Clin Med 115:233-240, 1990
185. English J, Evan A, Houghton DC, Bennett WM: Cyclosporine-induced acute renal dysfunction in rat. Transplantation 44:135-141, 1987
186. Burdmann EA, Andoh TF, Franceschini N, Fugihara C, Zatz R, Bennett WM: Acute renal failure after intravenous cyclosporine administration: Role of the vehicle. J Am Soc Nephrol 5:918, 1994 (abstr)
187. Perico N, Zoja C, Benigni A, Ghilardi F, Gualandris L, Remuzzi G: Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: Possible relevance to the reduction in glomerular filtration rate. J Pharmacol Exp Ther 239:229-235, 1986
188. McAuley FT, Whiting PH, Thomson AW, Simpson JG: The influence of enalapril or spronolactone on experimental cyclosporin nephrotoxicity. Biochem Pharmacol 36:699-703, 1987
189. Moss NG, Powell SL, Falk RJ: Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci U S A 82:8222-8226, 1985
190. Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG: Cyclosporine and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T cell signaling. Circ Res 73:596-602, 1993
191. Coffman TM, Carr DR, Yarger WE, Klotman PE: Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 43:282-285, 1987
192. Van der Heide JJH, Bilo HJG, Donker JM, Wilmink JM, Tegzecs AM: Effects of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 329:769-773, 1993
193. Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, Abrams J, Ryan D, Kelley VR: Delayed omega-3 fatty acid supplements in renal transplantation: A double blind placebo controlled study. Transplantation 59:352-356, 1995
194. Kon V, Sugiura M, Inagami T, Harrie BR, Ichikawa I, Hoover RL: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 37:1487-1491, 1990
195. Fogo A, Hellings SE, Inagami T, Kon V: Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int 42:770-774, 1992
196. Hunley T, Fogo A, Iwasaki S, Kon V: Endothelin A receptor (EtA) mediates functional but not structural damage in chronic cyclosporine nephrotoxicity (Cy). J Am Soc Nephrol 5:1718-1723, 1995
197. Elzinga L, Rosen S, Bennett WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol 4:214-221, 1993
198. Pichler R, Franceschini N, Young B: Does angiotensin II mediate cyclosporine nephropathy? J Am Soc Nephrol 5:929, 1994 (abstr)
199. Ghiggeri GM, Altieri P, Oleggini R, Valente F, Perfumo F, Gusmano R: Selective enhancement of collagen expression by cyclosporin with renal cells in vitro. J Am Soc Nephrol 4:753, 1994
200. Shihab FS, Andoh TF, Tanner AM, Noble NA, Franceschini N, Bennett WM: Fibrosis in chronic renal cyclosporine (CsA) toxicity: Preferential expression in medulla. J Am Soc Nephrol 6:1004, 1995 (abstr)
201. Meister B, Lippoldt A, Bunnemann B, Inagami T, Ganten D, Fuxe K: Cellular expression of angiotensin type-1 receptor mRNA in the kidney. Kidney Int 44:331-336, 1993
202. Sugiura M, Inagami T, Kon V: Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun 161:1220-1227, 1989
203. Van Buren D, Van Buren CT, Flechner SM, Maddox AM, Verani R, Kahan BD: De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 98:54-62, 1985
204. McCauley J, Bronsther O, Fung J, Todo S, Starzl TE: Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet 23/30:1516, 1989
205. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RA, Burnett JC, Jr: Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 69:1182-1193, 1994
206. Curtis JJ, Dubovsky E, Whelchel JD, Luke RG, Diethelm AG, Jones P: Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 2:477-479, 1986
207. Richards NT, Poston L, Hilston PJ: Cyclosporin A inhibits endothelium-dependent, prostanoid-induced relaxation in human subcutaneous resistance vessels. J Hypertens 8:159-163, 1990
208. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM: Vascular mechanisms of cyclosporine-induced hypertension in the rat. J Clin Invest 93:2244-2250, 1994
209. Diederich D, Yang Z, Lüscher TF: Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 2:1291-1297, 1992
210. Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura J: Long-term cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 7:249-252, 1993
211. Tejani A, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, Khawar MR: Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 33:729-734, 1988
212. Nyrop M, Olgaard K: Cyclosporin A treatment of severe steroid resistant nephrotic syndrome in adults. J Intern Med 227:65-68, 1990
213. Meyrier A, Noel L-H, Auriche P, Callard P: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 45:1446-1456, 1994
214. Ittel TH, Clasen W, Fuhs M, Kindler J, Mihatsch MJ, Sieberth HG: Long-term cyclosporin A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin Nephrol 44:156-162, 1995
215. Vonderscher J, Meinzer A: Rationale for the development of sandimmune neoral. Transplant Proc 26:2925-2927, 1994
216. Levy G, Grant D: Potential for CsA - Neoral in organ transplantation. Transplant Proc 26:2932-2934, 1994
217. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Kutz K: The pharmacokinetics of Sandimmun Neoral: A new oral formulation of cyclosporine. Transplant Proc 26:2935-2939, 1994
218. Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Chang C, Choc M, Wong R: The neoral formulation: Improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 26:2940-2943, 1994
219. Frei U, Taesch S, Niese D: Use of Sandimmun neoral in renal transplant patients. Transplant Proc 26:2928-2931, 1994
220. Burdmann EA, Andoh TF, Rosen S, Lindsley J, Munar M, Elzinga LW, Bennett WM: Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney Int 45:684-691, 1994
221. Hirstand C, Graber M, Hurtenbach U, Herrman P, Cammisuli S, Richardson BP, Eberle MK, Donatsch P, Ryffel B, Borel JF: New cyclosporine derivative SD2 IMM 125: In vitro and in vivo pharmacologic effects and toxicologic evaluation. Transplant Proc 25:691-692, 1993
222. Peters DH, Fitton A, Plosker GL, Faulds D: Tacrolimus: A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46:746-794, 1993
223. Venkataramanan R, Jain A, Warty VW, Abu-Elmagd K, Furakawa H, Imventarza O, Fung J, Todo S, Starzl TE: Pharmacokinetics of FK 506 following oral administration: A comparison of FK 506 and cyclosporine. Transplant Proc 23:931-933, 1991
224. Beysens AJ, Wijnen RMH, Beuman GH, van der Heyden J, Kootstra G, van As H: FK506: Monitoring in plasma or in whole blood? Transplant Proc 23:2745-2747, 1991
225. Jusko WJ, D'Ambrosio R: Monitoring FK 506 concentrations in plasma and whole blood. Transplant Proc 23:2732-2735, 1991
226. Warty VS, Venkataramanan R, Zendehrouh P, Mehta S, McKaveney T, Flowers J, Zuckerman S, Krajak A, Zeevi A, Fung J, Todo S, Starzl TE: Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc 23:2730-2731, 1991
227. Venkataramanan R, Jain A, Warty VS, Abu-Elmagd K, Alessiani M, Lever J, Krajak A, Flowers J, Mehta S, Zuckerman S, Fung J, Todo S, Starzl TE: Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 23:2736-2740, 1991
228. Harding MW, Galat A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-polylisomerase. Nature 341:758-760, 1989
229. Sehgal SN, Bansbach CC: Rapamycin: In vitro profile of a new immunosuppressive macrolide. Ann N Y Acad Sci U S A 685:58-67, 1993
230. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 87:9231-9235, 1990
231. Parsons WH, Sigal NH, Wyvratt MJ: FK-506 - A novel immunosuppressant. Ann N Y Acad Sci U S A 685:22-36, 1993
232. Sigal NH, Dumont FJ: Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10:519-560, 1992
233. Thompson AW: FK-506: Profile of an important new immunosuppressant. Transplant Rev 4:1-13, 1990
234. Connolly JO, Gane E, Higgins RM, O'Donnell PJ, Devlin J, Scoble JE, Williams R: Renal arteriopathy associated with FK 506 therapy following liver transplantation. Nephrol Dial Transplant 9:834-836, 1994
235. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ: The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Am J Surg Pathol 17:60-68, 1993
236. Nalesnik MA, Lai HS, Murase N, Todo S, Starzl TE: The effect of FK506 and CyA on the Lewis rat renal ischemia model. Transplant Proc 22:87-89, 1990
237. Klintmalm G: A review of FK506: A new immunosuppressant agent for the prevention and rescue of graft rejection. Transplant Rev 8:53-63, 1994
238. Takeda Y, Yoneda T, Ito Y, Miyamori I, Takeda R: Stimulation of endothelin mRNA and secretion in human endothelial cells by FK506. J Cardiovasc Pharmacol 22:S310-S312, 1992 (suppl 8)
239. Roullet JB, Xue H, Andoh TF, Burdmann EA, Chapman J, McCarron DA, Bennett WM: Cardiovascular and renal consequences of immunosuppression: Adverse effect of FK506 on vascular reactivity. J Hypertens 12:8121, 1994 (suppl 3)
240. Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J, Selby R, Starzl TE: Adverse effects associated with the use of FK 506. Transplant Proc 23:3105-3108, 1991
241. McCauley J, Shapiro R, Scantlebury VP, Gilboa N, Jordan M, Jensen C, Naik A, Tzakis A, Ellis D, Starzl TE: FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc 23:3354-3356, 1991
242. Cardenas ME, Zhu D, Heitman J: Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr Opin Nephrol Hypertens 4:472-477, 1995
243. Gregory CR, Huie P, Billingham ME, Morris RE: Rapamycin inhibits arterial intimai thickening caused by both alloimune and mechanical injury (its effect on cellular, growth factor, and cytokine responses in injured vessels). Transplantation 55:1409-1418, 1993
244. Camardo JS, Scarola JA, Maida BT, Sehgal SN: Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens 4:482-487, 1995
245. Sommer BG, Henry M, Ferguson RM: Sequential antilymphoblast globulin and cyclosporine for renal transplantation. Transplantation 43:85-90, 1987
246. Forsythe JLR: ATG - A polyclonal sledgehammer? Trans Immunol 2:148-152, 1994
247. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497, 1975
248. Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985
249. DeMattos AM, Norman DJ: OKT3 for treatment of rejection in renal transplantation. Clin Transpl 7:374-381, 1993
250. Chang TW, Kung PC, Gingras SP, Goldstein G: Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc Natl Acad Sci U S A 78:1805-1808, 1981
251. Roitt IM: OKT3: Immunology, production, purification, and pharmacokinetics. Clin Transpl 7:367-373, 1993
252. Schroeder TJ, Michael AT, First MR, Hariharan S, Bhat G, Hanto DW, Ryckman FC, Balistreri WF: Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status. Ther Drug Monit 16:361-367, 1994
253. Sutherland FR, Aboujaoude M, White MJ, Yamada J, Ghent C, Grant D, Wall W, Garcia B, Mazaheri R, Lazarovits AI: Mechanisms of rejection during OKT3 therapy: Propagation and characterization of CD3 resistant allospecific cytotoxic T cells from a rejecting liver allograft. Clin Immunol Immunopathol 60:40-54, 1991
254. Goldstein G, Fuccello AJ, Norman DJ, Shield CF III, Colvin RB, Cosimi AB: OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42:507-516, 1986
255. Alloway R, Kotb M, Hathaway D, Ohman M, Strain S, Gaber AO: The pharmacokinetic profile of standard and low-dose OKT3 induction immunosuppression in renal transplant recipients. Transplantation 58:249-253, 1994
256. Sancho J, Silverman LB, Castigli E, Ahem D, Laudano AP, Terhorst C, Geha RS, Chatila TA: Developmental regulation of transmembrane signaling via the T cell antigen receptor/CD3 complex in human T lymphocytes. J Immunol 148:1315-1321, 1992
257. Weiss A: T cell antigen receptor signal transduction: A tale of tails and cytoplasmic protein-tyrosine kinases. Cell 73:209-212, 1993
258. Krammer GM, Kurrasch R, Scillian JJ: Capping of the surface OKT3 binding molecule prevents the T-cell proliferative response to antigens: Evidence that this molecule conveys the activation signal. Cell Immunol 87:284-294, 1984
259. Pisa EK, Pisa P, Hansson M, Wigzell H: OKT3-induced cytokine mRNA expression in human peripheral blood mononuclear cells measured by polymerase chain reaction. Scand J Immunol 36:745-749, 1992
260. Parlevliet KJ, Schellekens PTA: Monoclonal antibodies in renal transplantation: A review. Transpl Int 5:234-246, 1992
261. Rinnooy KEA, Wright SD, Welte K, Wang CY: Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cell Immunol 98:181-187, 1986
262. Landegren U, Andersson J, Wigzell H: Mechanism of T lymphocyte activation by OKT3 antibodies: A general model for T cell induction. Eur J Immunol 14:325-328, 1984
263. Landegren U, Ramstedt U, Axberg I, Ullberg M, Jondal M, Wigzell H: Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu-2a antibodies. Eur J Immunol 14:325-328, 1984
264. Henell KR, Bakke A, Kenny TA, Kimball JA, Barry JM, Norman DJ: Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies. Transplant Proc 23:1070-1071, 1991
265. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, DePauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C: Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47:606-608, 1989
266. Costanzo-Nordin MR: Cardiopulmonary effects of OKT3: Determinants of hypotension, pulmonary edema and cardiac dysfunction. Transplant Proc 25:21-24, 1993
267. Bemelman FJ, Parlevliet KJ, Schellekens PT, Surachno S, van Royen EA, ten Berge RJ: Sequestration of labelled granulocytes in the lungs following administration of OKT3 is dose-dependent. Trans Immunol 2:47-51, 1994
268. Chatenoud L, Legendre C, Ferran C, Bach J-F, Kreis H: Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-Dosage and kinetics prerequisites. Transplantation 51:334-338, 1991
269. Goldman M, Abramowicz D, De Pauw L, Alegre ML, Widera I, Vereerstraeten P, Kinnaert P: OKT3-induced cytokine release: Attenuation by high-dose methylprednisolone. Lancet 2:802-803, 1989
270. Charpentier B, Hiesse C, Ferran C, Lantz O, Fries D, Bach J-F, Chatenoud L: Acute clinical syndrome associated with OKT3 administration: Prevention by single injection of an anti-human TNF monoclonal antibody. Presse Med 20:2009-2011, 1991
271. Schandene L, Gerard C, Crusiaux A, Abramowicz D, Velu T, Goldman M: Interleukin-10 inhibits OKT3-induced cytokine release: In vitro comparison with pentoxifylline. Transplant Proc 25:55-56, 1993 (suppl 1)
272. Shield CF III, Kahana L, Pirsch J, Vergne-Marini P, First MR, Schroeder TJ, Cohen D, Norman DJ, Monaco A, Martinez A, Dinarello CA, Dehlinger J, Wu SC, VanHorn A: Use of indomethacin to minimize the adverse reactions associated with Orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 54:164-165, 1992
273. Alegre M, Gastaldello K, Abramowicz D, Kinnaert P, Vereerstraeten P, De Pauw L, Vanderabeele P, Moser M, Leo O, Goldman M: Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52:674-679, 1991
274. Norman DJ, Kimball JA, Bennett WM, Shihab F, Batiuk TD, Meyer MM, Barry JM: A prospective, double-blind, randomized study of high versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transpl Int 7:356-361, 1994
275. Batiuk T, Bennett WM, Meyer M, Norman DJ: Cytokine nephropathy during antilymphocyte therapy. Transpl Proc 25:27-30, 1993 (suppl 1)
276. Chan GL, Weinstein SS, Wright CE, Bowers VD, Alveranga DY, Shires DL, Ackerman JR, Le For WW, Kahana L: Encephalopathy associated with OKT3 administration: Possible interaction with indomethacin. Transplantation 52:148-150, 1991
277. Shihab F, Barry JM, Norman DJ: Encephalopathy following the use of OKT3 in renal allograft transplantation. Transplant Proc 25:31-34, 1993 (suppl 1)
278. Thistlethwaite JR, Jr, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, Stuart FP: Complications and monitoring of OKT3 therapy. Am J Kidney Dis 11:112-119, 1988
279. Hanto DW, Jendrisak MD, So SKS, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T: Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Transplantation 57:377-384, 1994
280. Cole EH, Cattran DC, Farewell VT, Aprile M, Bear RA, Pei YP, Fenton SS, Tober JL, Cardella CJ: A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 57:60-67, 1994
281. Turner MC, Holman JM: Late reactions during initial OKT-3 treatment. Clin Transplant 7:1-3, 1993
282. Vigeral P, Chkoff A, Chatenoud L, Campos H, Lacombe M, Droz D, Goldstein G, Bach J-F, Kreis H: Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients: Utilization of OKT3 as the sole immunosuppressive agent. Transplantation 41:730-733, 1986
283. Norman DJ, Kahana L, Stuart FP, Thistlethwaite JR, Jr, Shield CF III, Monaco A, Dehlinger J, Shu-Chen W, Van Horn A, Haverty TP: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55:44-50, 1993
284. Norman DJ: The clinical role of OKT3. Immunol Allergy Clin North Am 9:95-107, 1989
285. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, Hansen WP, Delmonico FL, Russell PS: Use of monoclonal antibodies to T cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305:308-314, 1981
286. Odum J, Woodroffe AJ, Bannister KM, Clarkson AR: Use of OKT3 and cyclosporin A to treat idiopathic focal segmentai glomerulosclerosis. Clin Nephrol 39:230, 1993
287. Schroeder TJ, First MR: Monoclonal antibodies in organ transplantation. Am J Kidney Dis 23:138-147, 1994
288. Cosimi AB: Future of monoclonal antibodies in solid organ transplantation. Dig Dis Sci 40:65-72, 1995
289. Wright A, Shin SU, Morrison SL: Genetically engineered antibodies: Progress and prospects. Crit Rev Immunol 12:125-168, 1992
290. Burton DR, Barbas CF III: Human monoclonal antibodies: Recent achievements. Hosp Pract 29:111-122, 1994
291. Alegre M, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Jr, Zivin RA, Jolliffe LK, Bluestone J: A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57:1537-1543, 1994
292. Alegre M-L, Lenschow DJ, Bluestone JA: Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors. Dig Dis Sci 40:58-64, 1995
293. Upjohn: Atgam (package insert). Upjohn, Kalamazoo, MI, March 1993
294. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS: Biological and immunological characterization of ATG and ALG. Blood 68:712-719, 1986
295. Shenton BK, White MD, Bell AE, Clark K, Rigg KM, Forsythe JLR, Proud G, Taylor RM: The paradox of ATG monitoring in renal transplantation. Transplant Proc 26:3177-3180, 1994
296. Bonnefoy-Berard N, Verrier B, Vincent C, Revillard JP: Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. Immunology 77:61-67, 1992
297. MacDonald P, Mundy J, Keogh A, Chang VP, Spratt P: A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation - Increased morbidity with OKT3. Transplantation 55:110-116, 1993
298. Light JA, Biggers JA, Fernandez-Bueno C, Reinmuth BW: Sequential antilymphocyte globulin (ALG) therapy (RX) improves graft and patient survival. Transplant Proc 15:622-626, 1983
299. Richardson AJ, Higgins RM, Liddington M, Murie J, Ting A, Morris PJ: Antithymocyte globulin for steroid resistant rejection in renal transplant recipients immunosuppressed with triple therapy. Transpl Int 2:27-32, 1989
300. Pescovitz MD, Book BK, Milgrom ML, Leapman SB, Petersen B, Filo RS: Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts. Surgery 116:811-818, 1994
301. Levy M, Spino M, Read SE: Colchicine: A state-of-the-art review. Pharmacotherapy 11:196-211, 1991
302. Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM: Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 46:351-354, 1994
303. Ben-Chetrit E, Scherrmann J-M, Zylber-Katz E, Levy M: Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 21:710-713, 1994
304. DeLannoy IAM, Mandin RS, Silverman M: Renal secretion of vinblastine, vincristine and colchicine in vivo. J Pharmacol Exp Ther 268:388-395, 1993
305. Skoufias DA, Wilson L: Mechanism of inhibition of microtubule polymerization by colchicine: Inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 31:738-746, 1992
306. Sackett DL, Varma JK: Molecular mechanism of colchicine action: Induced local unfolding of β-tubulin. Biochemistry 32:13560-13565, 1993
307. Mekori YA, Chowers Y, Drucker I, Klajman A: Inhibition of delayed hypersensitivity reactions by colchicine. II. Colchicine inhibits interferon-gamma induced expression of HLA-DR on gut epithelial cell line. Clin Exp Immunol 78:230-232, 1989
308. Ding AH, Porteiu F, Sanchez E, Nathan CF: Down-regulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. J Exp Med 171:715-727, 1995
309. Marczin N, Papapetropoulous A, Jilling T, Catravas JD: Prevention of nitric oxide synthase induction in vascular smooth muscle cells by microtubule depolymerizing agents. Br J Pharmacol 109:603-605, 1993
310. Ostermann D, Perico N, Imberti O, Barbui C, Bontempelli M, Remuzzi G: Colchicine allows prolonged survival of highly reactive renal allograft in the rat. J Am Soc Nephrol 4:1294-1299, 1993
311. Sanders PW: Potential role of colchicine in the prevention of cast nephropathy from Bence Jones proteins. Contrib Nephrol 101:104-108, 1993
312. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M: Colchicine treatment of AA amyloidosis of familial mediterranean fever: An analysis of factors affecting outcome. Arthritis Rheum 37:1804-1811, 1994
313. Fak AS, Ozener C, Akoglu E: Colchicine and secondary amyloidosis. Ann Intern Med 117:795-796, 1992
314. Zemer D, Livneh A, Langevitz P: Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 116:426, 1992
315. Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M: Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 60:418-422, 1992
316. Invernizzi F: Colchicine and mixed cryoglobulinemia. Arthritis Rheum 36:722-723, 1993
317. Nord y A: Is there a rational use for omega-3 fatty acids (fish oils) in clinical medicine? Drugs 42:331-342, 1991
318. Raper NR, Cronin FJ, Exler J: Omega-3 fatty acid content of the U.S. food supply. J Am Coll Nutr 11:304-308, 1992
319. De Caterina R, Endres S, Kristensen SD, Schmidt EB: n-3 Fatty acids and renal diseases. Am J Kidney Dis 24:397-415, 1994
320. De Caterina R, Caprioli R, Giannessi D, Sicari R, Galli C, Lazzerini G, Bernini W, Carr L, Rindi P: n-3 Fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney Int 44:843-850, 1993
321. Weise WJ, Natori Y, Levine JS, O'Meara YM, Minto AW, Manning EC, Goldstein DJ, Abrahamson DR, Salant DJ: Fish oil has protective and therapeutic effects on proteinuria in passive Heymann nephritis. Kidney Int 43:359-368, 1993
322. Scharschmidt LA, Gibbons NB, McGarry L, Berger P, Axelrod M, Janis R, Ko YH: Effects of dietary fish oil on renal insufficiency in rats with subtotal nephrectomy. Kidney Int 32:700-709, 1987
323. Clark WF, Parbtani A, Philbrick DJ, Spanner E, Huff MW, Holub BJ: Dietary protein restriction versus fish oil supplementation in the chronic remnant nephron model. Clin Nephrol 39:295-304, 1993
324. Düsing R, Struck A, Göbel BO, Weisser B, Vetter H: Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 38:315-319, 1990
325. Søyland E, Nenseter MS, Braathen L, Drevon CA: Very long chain n-3 and n-6 polyunsaturated fatty acids inhibit proliferation of human T-lymphocytes in vitro. Eur J Clin Invest 23:112-121, 1993
326. Connor WE: Omega-3 fatty acids and heart disease, in Kritchevsky D, Carroll KK (eds): Nutrition and Disease Update: Heart Disease. Champaign,IL, American Oil Chemists' Society Press, 1994, pp 7-42
327. Ackman RG: The absorption of fish oils and concentrates. Lipids 27:858-862, 1992
328. Donadio JV, Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE, Mayo Nephrology Collaborative Group: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331:1194-1199, 1994
329. Bennett WM, Walker RG, Kincaid-Smith P: Treatment of IgA nephropathy with eicosapentanoic acid (EPA): A two-year prospective trial. Clin Nephrol 31:128-131, 1989
330. Clark WF, Parbtani A, Naylor CD, Levinton CM, Muirhead N, Spanner E, Huff MW, Philbrick DJ, Holub BJ: Fish oil in lupus nephritis: Clinical findings and methodological implications. Kidney Int 44:75-86, 1993
331. Keogh A, Spratt P, McCosker C, MacDonald P, Mundy J, Kaan A: Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 333:628-633, 1995
332. Katznelson S, Kobashigawa JA: Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int 48:S-112-S-115, 1995 (suppl 52)
333. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333:621-627, 1995